<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>168-DERIVATIVES-OF-AMINOSALICYLIC-ACID-(ASA).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DERIVATIVES OF AMINOSALICYLIC ACID (ASA)" code="A07EC-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG2>
<DESCRIPTION>Risk of increase of the myelosuppression of the immunomodulator by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TMPT)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
